Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Lipid disorders are highly prevalent among patients with advanced chronic kidney disease (CKD) and end-stage renal disease (ESRD), contributing substantially to cardiovascular risk. However, the relative efficacy and renal safety of fibrates compared with statins in these populations remain uncertain, as existing studies yield inconsistent findings.
A systematic search of PubMed, Scopus, Web of Science, and Google Scholar was conducted through September 2025. Eligible studies included randomized controlled trials and large observational cohorts comparing fibrates (e.g., fenofibrate, gemfibrozil) with statins (e.g., atorvastatin, simvastatin) in adults with advanced CKD (stages 3–5) or ESRD. Random-effects meta-analyses were performed. Primary outcomes included changes in lipid parameters and renal biomarkers.
Four studies met the inclusion criteria for the systematic review, with a total of 193 patients included in the quantitative synthesis. Pooled analyses revealed no significant differences between fibrates and statins in lipid outcomes, including LDL cholesterol (mean difference [MD] 26.15 mg/dL; 95% CI –1.7 to 54.0; P = 0.07), triglycerides (MD –19.17 mg/dL; 95% CI –46.6 to 8.27; P = 0.17), total cholesterol (MD 31.3 mg/dL; 95% CI –9.4 to 72.1; P = 0.13), and HDL cholesterol (MD 5.1 mg/dL; 95% CI –3.35 to 13.57; P = 0.24). Similarly, no significant differences were observed in renal function parameters, including serum creatinine (P = 0.57), urea (P = 0.42), and potassium levels (P = 0.31).
Fibrates and statins demonstrate comparable efficacy in lipid modification and similar renal safety profiles among patients with advanced CKD and ESRD. These findings suggest that either class may be considered for lipid management in this high-risk population, although larger, well-powered randomized trials are warranted to confirm long-term outcomes.
